3881 news items
Page 5 of 100
i0knf60h800gq 7gyl
AS
21 May 24
, including, without limitation, our reports on Form 20-F and Form 6-K. You are urged to consider
krw0qbd
PHGE
21 May 24
and uncertainties described under the caption "Risk Factors" in BiomX's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC
9meombk3c 5pzmtrhx2vgm4ytziikfimk2yah68qe
EXP
21 May 24
measure calculated by excluding non-routine items and certain non-cash expenses in the manner described in Attachment 6
70et20zvaxflarf3qauj28eq0csu6ifmpkws7p3qs028um7cc5groiu1kox
IRWD
21 May 24
and adolescents aged 6 to 17 years with functional constipation. The recommended dose is 290 mcg for IBS-C patients and 145 mcg for CIC patients
aer7i4w3gea5d1lwoz9b4se498l07jslndfjoop05ixrlrflxxfe
AEIS
21 May 24
at £468m (the "Latest Proposal") and reflecting the increased number of shares following XP Power's November 6, 2023 equity raise executed at £11.50 per
rbmeyy84hyj z0qg621mli59npeyydi4s95rv4ja1a71rdtvor0pv6cf88
PRKA
20 May 24
shareholders outlining the clear choice hanging in the balance at its annual meeting of shareholders scheduled for June 6, 2024. Dear
twyhngw h8vkoy7ny3j24z1ig2dhwjoxmtz4mfrgig
ALVO
20 May 24
psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Use of Trademarks
zlaock7 mkokvoqins
ALVO
TEVA
20 May 24
to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6
9dx3y0gm65954levbk0o95cljiv o1o0aqci03gwuh
OI
20 May 24
of the Company's customer base, (6) the Company's ability to improve its glass melting technology, known as the modular advanced glass manufacturing asset ("MAGMA
4gua8t 4zkhu5nx0m02n
20 May 24
by the senior executive, the notice period may not exceed 6 months, without entitlement to severance pay. In addition to fixed cash salary during
1ik3of9otj6el5yykpypedako5rlktbncg393rswe
CORBF
20 May 24
announced a transaction through a Form 6-K filing with the U.S. Securities and Exchange Commission (SEC), disclosing its decision to acquire biotechnology
gdh9zy6wa8ct fb
BYFC
20 May 24
its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the "Q3 2023 Form 10-Q"), or its Annual Report on Form 10-K for the fiscal
cqmyxu7dzj89yfrfbr5gxh534 pkab2eplgpjvawrgql24mk1d
CHUC
20 May 24
)Revenue decreased 24% to $3.1 millionGross profit increased 6% to $0.9 millionOperating expenses decreased 22% to $1.9 million
iiucsxax03e4jfpd muchqm258u97ybqchpvcwl40o
ZEPP
20 May 24
6
c1cjjy4z
AA
20 May 24
following completion of the proposed transaction; (6) failure to realize the anticipated benefits of the proposed transaction; (7) the occurrence
ajvhxznueulzvguc7gj0qugy8v9a8b1q296hnoapb upia2svnns6a
NDSN
20 May 24
coatings systems and packaging product lines. Operating profit was $118 million, an increase of $6 million from the prior year. EBITDA in the quarter
efpbow5 vqd7yyq0rgxgewlfy3jv2tqsrxpf1leb
BRAC
20 May 24
It For additional information on the proposed business combination, see the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange
tjougocsatiikqm72gv
INSM
20 May 24
—
—QOL-B Respiratory Domain Scores for ARIKAYCE Patients Showed Improvement Through Month 6 and Continued to Improve
wrgo03dxb73iv3 8j8tkodjepa0b7
DGLY
20 May 24
profits for the three months ended March 31, 2024 and 2023 were $565,694 and $534,195, respectively, an improvement of $31,499 (6%). The entertainment
f404f59ui 0d6
RBT
20 May 24
) Rubicon's execution of anticipated operational efficiency initiatives, cost reduction measures and financing arrangements; and 6) other risks